AQR Capital Management
FENC icon

AQR Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

AQR Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
24,146
+9,007
+59% +$69.5K ﹤0.01% 3648
2025
Q4 		$117K Buy
15,139
+127
+0.8% +$1.04K ﹤0.01% 3452
2025
Q3 		$141K Buy
15,012
+700
+5% +$6.06K ﹤0.01% 3324
2025
Q2 		$119K Buy
14,312
+3,415
+31% +$23.4K ﹤0.01% 3148
2025
Q1 		$66.4K Buy
+10,897
New +$70K ﹤0.01% 3065
2021
Q2 		– Sell
-12,977
Closed -$81K – 2251
2021
Q1 		$81K Sell
12,977
-3,614
-22% -$27.2K ﹤0.01% 2162
2020
Q4 		$124K Sell
16,591
-5,168
-24% -$39.4K ﹤0.01% 2137
2020
Q3 		$132K Buy
+21,759
New +$153K ﹤0.01% 2110
2018
Q4 		– Sell
-20,560
Closed -$169K – 2217
2018
Q3 		$169K Buy
20,560
+4,429
+27% +$41.1K ﹤0.01% 2218
2018
Q2 		$168K Buy
+16,131
New +$191K ﹤0.01% 2243

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

AQR Capital Management's FENC Position: Q1 2026 in Review

AQR Capital Management increased its Fennec Pharmaceuticals (FENC) stake by 59% in Q1 2026, buying an estimated $69.5K and bringing the position to 24,146 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

AQR Capital Management first reported a position in FENC in Q2 2018 and has held it in 10 quarters since. The position peaked at $169K in Q3 2018. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • AQR Capital Management held 24,146 shares of Fennec Pharmaceuticals worth $148K as of Q1 2026.
  • AQR Capital Management bought 9,007 Fennec Pharmaceuticals shares in Q1 2026, an estimated $69.5K.
  • Fennec Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3648 holding.
  • AQR Capital Management first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 10 quarters since.
  • AQR Capital Management's Fennec Pharmaceuticals position peaked at $169K in Q3 2018.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.